Business Context and Reporting Period
Bicycle Therapeutics plc filed a current report on Form 8-K dated February 21, 2020; the filing was signed and includes a February 25, 2020 press release. The company reported entering into a material definitive agreement with Genentech, a member of the Roche Group, focused on discovering and developing Bicycle peptides for immuno-oncology targets.
Key Financial and Operating Metrics
- Genentech will pay Bicycle an upfront payment of $30.0 million.
- Genentech may nominate up to two additional immuno-oncology targets, with an expansion fee of $10.0 million per additional collaboration program.
- Genentech may elect to advance candidates and obtain exclusive worldwide rights in exchange for success-based milestone payments totaling $10 million to $12 million per collaboration program.
- Bicycle is eligible for development, regulatory, and initial commercialization milestones totaling up to $200.0 million per collaboration program.
- Bicycle is also eligible for up to $200.0 million in sales milestones on a product-by-product basis.
- Commercialized products would generate tiered royalties on net sales ranging from the mid-single digits to low double digits, subject to customary reductions and offsets.
- The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or balance-sheet amounts.
Material Changes Versus the Prior Comparable Period
The filing does not present comparative financial results. The material development is the new Genentech collaboration, which adds a $30.0 million upfront payment opportunity and potential milestone and royalty economics to Bicycle’s business.
Guidance, Outlook, Risks, and Unusual Items
- Bicycle will conduct discovery and lead-optimization activities through specified collaboration phases under a mutually agreed research plan and joint research committee oversight.
- The initial work will address two immuno-oncology targets, with potential expansion to two additional targets. Up to four development candidates may be pursued.
- After candidate selection, Genentech will be responsible for future research and development and may obtain exclusive development and commercialization rights.
- Genentech may terminate the agreement for convenience, subject to specified notice periods, in its entirety, by program, or by major market. Either party may terminate for an uncured material breach or insolvency.
- Milestone payments and royalties are contingent on target selection, development progress, regulatory and commercialization events, sales, and product commercialization; none of these amounts is guaranteed.
- The filing states that its agreement description is qualified by the complete agreement, which was expected to be filed as an exhibit to Bicycle’s Annual Report on Form 10-K for the year ended December 31, 2019.
Important Facts for Investors to Verify
- Receipt, timing, and accounting treatment of the $30.0 million upfront payment.
- Specific research obligations, payment triggers, target-selection rights, and termination provisions in the complete collaboration agreement.
- Whether Genentech exercises options for additional targets or exclusive development and commercialization rights.
- Achievement of development, regulatory, sales, and commercialization milestones and the resulting cash payments.
- Future financial statement disclosures regarding collaboration revenue, deferred revenue, research costs, liquidity, and any related commitments.